The Plan announced October 10 2024 ! Non dilutive Funding ! The study’s primary endpoint was achieved by 60.3 per cent of all patients treated, which is well above the 50 per cent guideline specified by the International Bladder Cancer Group (a consortium of top uro-oncologists from around the world)
According to the World Cancer Research Fund, at least 614,298 cases of bladder cancer were reported globally in 2022.
Internationally, it is the 10th most common cancer, sixth in men, with little to no advancements made in treating the condition, until recently. The U.S. Food and Drug Administration has recognized the unmet medical need for treating BCG-Unresponsive NMIBC with the issuance of its BCG-Unresponsive Guidance for Industry in August 2024.
Theralase® has the potential to lock in strategic partnerships, licensing deals or straight acquisition of its technology for non-dilutive funding thanks to the success of its ongoing clinical study that has the potential to disrupt the market.
Latest data from bladder cancer study to propel future growth | 2024-10-10 | Investing News | Stockhouse